Business · NEWS EXPLAINER
AkzoNobel’s Q3 margin improves as portfolio exits push operating income to a loss
Pricing lifted organic sales and adjusted EBITDA edged higher, but Russia and Pakistan exit charges, weaker cash generation and a still-pending Axalta merger shape the fuller picture.
AkzoNobel reported a modest improvement in third-quarter adjusted profitability: adjusted EBITDA rose to €388 million from €385 million and the margin increased to 15.3% from 15.1%, helped by pricing and productivity.
The statutory and cash-flow picture was weaker. Operating income was a €73 million loss after charges tied mainly to the Russia deconsolidation, the Pakistan divestment and merger work, while cash from operations fell to €187 million from €331 million.
Adjusted improvement, statutory loss
The headline adjusted measure improved slightly, but it excludes items that matter to the reported accounts. AkzoNobel recorded a €230 million charge for deconsolidating its Russian activities, a €46 million charge related to the Pakistan divestment and costs connected with the planned Axalta combination. Those items help explain why operating income remained negative even as adjusted EBITDA and margin rose.
Organic growth did not become reported growth
Pricing contributed to 2% organic sales growth, but reported revenue slipped to €2.538 billion from €2.547 billion. Currency movements and portfolio changes can offset an underlying improvement, so the two growth descriptions answer different questions and should not be treated as contradictory.
Cash conversion weakened
Cash from operations dropped by €144 million year on year to €187 million. That decline does not erase the margin gain, but it means the quarter generated less operating cash to support debt reduction, investment or shareholder returns. The next results should show whether the drop was timing-related or more persistent.
The full-year target stays in place
Management kept 2026 adjusted EBITDA guidance at around €1.47 billion. The figure is an adjusted operating target, not a forecast for statutory profit or cash flow, and it excludes effects from the proposed Axalta merger.
Merger timing is a milestone, not a certainty
AkzoNobel and Axalta still expect their all-share merger to close in early 2027. The company says regulatory work is advancing, but completion remains conditional on approvals. Readers should separate that expected timetable from a completed transaction.
What matters next
The key checks are fourth-quarter pricing and volume, cash conversion, the treatment of portfolio-exit charges, delivery of the €1.47 billion adjusted EBITDA target and concrete regulatory or shareholder milestones for the Axalta deal. Together they will show whether the margin gain is durable and whether the merger timetable remains realistic.
